TTOO T2 BIOSYSTEMS INC

T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum. The conference is being held on November 15 at the Westin Grand Central in New York.

Mr. McDonough is scheduled to present on Thursday, November 15, 2018 at 11:00 a.m. ET. Mr. McDonough and John Sprague, chief financial officer, will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay, and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.

About T2 Biosystems:

T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit

Media Contact:

Gina Kent, Vault Communications



610-455-2763

Investor Contact:

Zack Kubow, W2O Group



415-946-1053 

EN
08/11/2018

Underlying

TTOOT2 BIOSYSTEMS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on T2 BIOSYSTEMS INC

 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 ...

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Achieved record fourth quarter and full-year 2024 sepsis product revenues LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2...

January 7, 2025 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing Euro...

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrume...

December 18, 2024 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test ...

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally Milestone demonstrates the growing customer adoption of the Company’s proprietary technology LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company’s direct-from-whole-blood technology. A meta-analysis of 14 c...

December 17, 2024 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supp...

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, ...

December 16, 2024 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Plans to License its Proprietary Technology to...

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in di...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch